nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—TNFSF11—Osteoclast Signaling—IFNB1—hepatitis B	0.0249	0.242	CbGpPWpGaD
Lenalidomide—Thalidomide—NFKB1—hepatitis B	0.0177	0.561	CrCbGaD
Lenalidomide—TNFSF11—blood—hepatitis B	0.0103	0.241	CbGeAlD
Lenalidomide—Pomalidomide—TNF—hepatitis B	0.00843	0.267	CrCbGaD
Lenalidomide—CDH5—blood—hepatitis B	0.00773	0.182	CbGeAlD
Lenalidomide—CDH5—liver—hepatitis B	0.00605	0.142	CbGeAlD
Lenalidomide—Thalidomide—TNF—hepatitis B	0.00543	0.172	CrCbGaD
Lenalidomide—CRBN—blood—hepatitis B	0.00491	0.115	CbGeAlD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—CTNNB1—hepatitis B	0.00469	0.0457	CbGpPWpGaD
Lenalidomide—CDH5—Adherens junctions interactions—CTNNB1—hepatitis B	0.00444	0.0432	CbGpPWpGaD
Lenalidomide—CRBN—liver—hepatitis B	0.00384	0.0902	CbGeAlD
Lenalidomide—PTGS2—blood plasma—hepatitis B	0.00365	0.0857	CbGeAlD
Lenalidomide—PTGS2—Eicosanoid Synthesis—GGT2—hepatitis B	0.00363	0.0354	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—NFKB1—hepatitis B	0.0035	0.0341	CbGpPWpGaD
Lenalidomide—Pain in extremity—Telbivudine—hepatitis B	0.00334	0.00406	CcSEcCtD
Lenalidomide—Migraine—Telbivudine—hepatitis B	0.00329	0.00399	CcSEcCtD
Lenalidomide—Neutropenia—Entecavir—hepatitis B	0.00329	0.00399	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Entecavir—hepatitis B	0.00327	0.00397	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—TGFB1—hepatitis B	0.00325	0.0316	CbGpPWpGaD
Lenalidomide—Rhinorrhoea—Lamivudine—hepatitis B	0.0032	0.00389	CcSEcCtD
Lenalidomide—Hyperglycaemia—Entecavir—hepatitis B	0.00317	0.00385	CcSEcCtD
Lenalidomide—Dysphonia—Lamivudine—hepatitis B	0.00315	0.00383	CcSEcCtD
Lenalidomide—Weight decreased—Adefovir Dipivoxil—hepatitis B	0.0031	0.00377	CcSEcCtD
Lenalidomide—Renal failure—Entecavir—hepatitis B	0.00308	0.00374	CcSEcCtD
Lenalidomide—Abdominal pain upper—Telbivudine—hepatitis B	0.00305	0.00371	CcSEcCtD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—CYP2A6—hepatitis B	0.00304	0.0297	CbGpPWpGaD
Lenalidomide—Cramp muscle—Telbivudine—hepatitis B	0.00301	0.00365	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Telbivudine—hepatitis B	0.00301	0.00365	CcSEcCtD
Lenalidomide—Renal failure—Adefovir Dipivoxil—hepatitis B	0.003	0.00365	CcSEcCtD
Lenalidomide—Haematuria—Entecavir—hepatitis B	0.00299	0.00363	CcSEcCtD
Lenalidomide—Nasopharyngitis—Telbivudine—hepatitis B	0.00299	0.00363	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Entecavir—hepatitis B	0.00296	0.0036	CcSEcCtD
Lenalidomide—Gastritis—Telbivudine—hepatitis B	0.00296	0.00359	CcSEcCtD
Lenalidomide—Muscular weakness—Telbivudine—hepatitis B	0.00295	0.00358	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Telbivudine—hepatitis B	0.00295	0.00358	CcSEcCtD
Lenalidomide—Rhabdomyolysis—Lamivudine—hepatitis B	0.00293	0.00356	CcSEcCtD
Lenalidomide—Haematuria—Adefovir Dipivoxil—hepatitis B	0.00291	0.00354	CcSEcCtD
Lenalidomide—Abdominal distension—Telbivudine—hepatitis B	0.00291	0.00353	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Adefovir Dipivoxil—hepatitis B	0.00289	0.00351	CcSEcCtD
Lenalidomide—Influenza—Telbivudine—hepatitis B	0.00289	0.00351	CcSEcCtD
Lenalidomide—Rectal haemorrhage—Lamivudine—hepatitis B	0.00287	0.00349	CcSEcCtD
Lenalidomide—Sinusitis—Adefovir Dipivoxil—hepatitis B	0.00287	0.00348	CcSEcCtD
Lenalidomide—Oropharyngeal pain—Lamivudine—hepatitis B	0.00285	0.00346	CcSEcCtD
Lenalidomide—Hepatitis—Entecavir—hepatitis B	0.00281	0.00342	CcSEcCtD
Lenalidomide—Oedema peripheral—Entecavir—hepatitis B	0.00277	0.00337	CcSEcCtD
Lenalidomide—Abdominal discomfort—Telbivudine—hepatitis B	0.00277	0.00336	CcSEcCtD
Lenalidomide—Hepatitis—Adefovir Dipivoxil—hepatitis B	0.00274	0.00333	CcSEcCtD
Lenalidomide—Hypercholesterolaemia—Lamivudine—hepatitis B	0.00274	0.00333	CcSEcCtD
Lenalidomide—Hearing impaired—Lamivudine—hepatitis B	0.00272	0.00331	CcSEcCtD
Lenalidomide—Pharyngitis—Adefovir Dipivoxil—hepatitis B	0.00272	0.00331	CcSEcCtD
Lenalidomide—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.00271	0.00329	CcSEcCtD
Lenalidomide—Neutropenia—Telbivudine—hepatitis B	0.0027	0.00328	CcSEcCtD
Lenalidomide—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.0027	0.00328	CcSEcCtD
Lenalidomide—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.00269	0.00327	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Telbivudine—hepatitis B	0.00268	0.00326	CcSEcCtD
Lenalidomide—Inflammation—Lamivudine—hepatitis B	0.00267	0.00325	CcSEcCtD
Lenalidomide—Musculoskeletal pain—Lamivudine—hepatitis B	0.00262	0.00319	CcSEcCtD
Lenalidomide—CDH5—Cell-cell junction organization—CTNNB1—hepatitis B	0.00255	0.0248	CbGpPWpGaD
Lenalidomide—Immune system disorder—Entecavir—hepatitis B	0.00254	0.00309	CcSEcCtD
Lenalidomide—Renal failure—Telbivudine—hepatitis B	0.00253	0.00307	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Telbivudine—hepatitis B	0.00252	0.00306	CcSEcCtD
Lenalidomide—Wheezing—Lamivudine—hepatitis B	0.00252	0.00306	CcSEcCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—hepatitis B	0.00249	0.0243	CbGpPWpGaD
Lenalidomide—Alopecia—Entecavir—hepatitis B	0.00249	0.00302	CcSEcCtD
Lenalidomide—Mental disorder—Entecavir—hepatitis B	0.00246	0.00299	CcSEcCtD
Lenalidomide—Malnutrition—Entecavir—hepatitis B	0.00245	0.00297	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—hepatitis B	0.00245	0.0238	CbGpPWpGaD
Lenalidomide—Neuropathy—Lamivudine—hepatitis B	0.00243	0.00296	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Telbivudine—hepatitis B	0.00243	0.00296	CcSEcCtD
Lenalidomide—Malnutrition—Adefovir Dipivoxil—hepatitis B	0.00239	0.0029	CcSEcCtD
Lenalidomide—Flatulence—Adefovir Dipivoxil—hepatitis B	0.00235	0.00286	CcSEcCtD
Lenalidomide—Mouth ulceration—Lamivudine—hepatitis B	0.00234	0.00285	CcSEcCtD
Lenalidomide—Gynaecomastia—Lamivudine—hepatitis B	0.00232	0.00282	CcSEcCtD
Lenalidomide—Back pain—Adefovir Dipivoxil—hepatitis B	0.00231	0.00281	CcSEcCtD
Lenalidomide—Hepatitis—Telbivudine—hepatitis B	0.00231	0.00281	CcSEcCtD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—hepatitis B	0.00231	0.0225	CbGpPWpGaD
Lenalidomide—Hypoaesthesia—Telbivudine—hepatitis B	0.0023	0.00279	CcSEcCtD
Lenalidomide—Pharyngitis—Telbivudine—hepatitis B	0.00229	0.00279	CcSEcCtD
Lenalidomide—Connective tissue disorder—Telbivudine—hepatitis B	0.00227	0.00276	CcSEcCtD
Lenalidomide—ABCB1—blood plasma—hepatitis B	0.00226	0.053	CbGeAlD
Lenalidomide—Sepsis—Lamivudine—hepatitis B	0.00225	0.00273	CcSEcCtD
Lenalidomide—Anaemia—Adefovir Dipivoxil—hepatitis B	0.00221	0.00268	CcSEcCtD
Lenalidomide—Lymphadenopathy—Lamivudine—hepatitis B	0.00221	0.00268	CcSEcCtD
Lenalidomide—Leukopenia—Entecavir—hepatitis B	0.00219	0.00266	CcSEcCtD
Lenalidomide—Sleep disorder—Lamivudine—hepatitis B	0.00217	0.00264	CcSEcCtD
Lenalidomide—Gastroenteritis—Lamivudine—hepatitis B	0.00212	0.00258	CcSEcCtD
Lenalidomide—Deafness—Lamivudine—hepatitis B	0.0021	0.00256	CcSEcCtD
Lenalidomide—Cough—Adefovir Dipivoxil—hepatitis B	0.00208	0.00253	CcSEcCtD
Lenalidomide—Mediastinal disorder—Telbivudine—hepatitis B	0.00208	0.00253	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.00207	0.00251	CcSEcCtD
Lenalidomide—Myalgia—Adefovir Dipivoxil—hepatitis B	0.00203	0.00247	CcSEcCtD
Lenalidomide—Chest pain—Adefovir Dipivoxil—hepatitis B	0.00203	0.00247	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00202	0.00245	CcSEcCtD
Lenalidomide—Malnutrition—Telbivudine—hepatitis B	0.00201	0.00244	CcSEcCtD
Lenalidomide—Infection—Entecavir—hepatitis B	0.00199	0.00241	CcSEcCtD
Lenalidomide—Dysgeusia—Telbivudine—hepatitis B	0.00197	0.00239	CcSEcCtD
Lenalidomide—Nervous system disorder—Entecavir—hepatitis B	0.00196	0.00238	CcSEcCtD
Lenalidomide—Back pain—Telbivudine—hepatitis B	0.00195	0.00236	CcSEcCtD
Lenalidomide—Skin disorder—Entecavir—hepatitis B	0.00194	0.00236	CcSEcCtD
Lenalidomide—Muscle spasms—Telbivudine—hepatitis B	0.00193	0.00235	CcSEcCtD
Lenalidomide—Hypoglycaemia—Lamivudine—hepatitis B	0.00193	0.00234	CcSEcCtD
Lenalidomide—CDH5—Cell junction organization—CTNNB1—hepatitis B	0.00193	0.0188	CbGpPWpGaD
Lenalidomide—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.00191	0.00232	CcSEcCtD
Lenalidomide—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.00191	0.00232	CcSEcCtD
Lenalidomide—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00189	0.0023	CcSEcCtD
Lenalidomide—Ill-defined disorder—Telbivudine—hepatitis B	0.00187	0.00227	CcSEcCtD
Lenalidomide—Anorexia—Adefovir Dipivoxil—hepatitis B	0.00186	0.00226	CcSEcCtD
Lenalidomide—Affect lability—Lamivudine—hepatitis B	0.00185	0.00225	CcSEcCtD
Lenalidomide—Migraine—Lamivudine—hepatitis B	0.00185	0.00225	CcSEcCtD
Lenalidomide—Malaise—Telbivudine—hepatitis B	0.00181	0.0022	CcSEcCtD
Lenalidomide—Insomnia—Entecavir—hepatitis B	0.00181	0.0022	CcSEcCtD
Lenalidomide—Mood swings—Lamivudine—hepatitis B	0.00178	0.00217	CcSEcCtD
Lenalidomide—Somnolence—Entecavir—hepatitis B	0.00178	0.00216	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.00178	0.00216	CcSEcCtD
Lenalidomide—Dyspepsia—Entecavir—hepatitis B	0.00176	0.00214	CcSEcCtD
Lenalidomide—Cough—Telbivudine—hepatitis B	0.00176	0.00213	CcSEcCtD
Lenalidomide—Dehydration—Lamivudine—hepatitis B	0.00175	0.00213	CcSEcCtD
Lenalidomide—Liver function test abnormal—Lamivudine—hepatitis B	0.00174	0.00211	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Entecavir—hepatitis B	0.00173	0.0021	CcSEcCtD
Lenalidomide—Fatigue—Entecavir—hepatitis B	0.00172	0.00209	CcSEcCtD
Lenalidomide—Abdominal pain upper—Lamivudine—hepatitis B	0.00172	0.00209	CcSEcCtD
Lenalidomide—PTGS2—Eicosanoid Synthesis—GGT1—hepatitis B	0.00172	0.0167	CbGpPWpGaD
Lenalidomide—Dyspepsia—Adefovir Dipivoxil—hepatitis B	0.00172	0.00208	CcSEcCtD
Lenalidomide—Arthralgia—Telbivudine—hepatitis B	0.00171	0.00208	CcSEcCtD
Lenalidomide—Myalgia—Telbivudine—hepatitis B	0.00171	0.00208	CcSEcCtD
Lenalidomide—Chest pain—Telbivudine—hepatitis B	0.00171	0.00208	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.0017	0.00207	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Lamivudine—hepatitis B	0.00169	0.00206	CcSEcCtD
Lenalidomide—Cramp muscle—Lamivudine—hepatitis B	0.00169	0.00206	CcSEcCtD
Lenalidomide—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.00169	0.00206	CcSEcCtD
Lenalidomide—Discomfort—Telbivudine—hepatitis B	0.00169	0.00206	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00168	0.00204	CcSEcCtD
Lenalidomide—Nasopharyngitis—Lamivudine—hepatitis B	0.00168	0.00204	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Lamivudine—hepatitis B	0.00166	0.00202	CcSEcCtD
Lenalidomide—Muscular weakness—Lamivudine—hepatitis B	0.00166	0.00202	CcSEcCtD
Lenalidomide—Abdominal distension—Lamivudine—hepatitis B	0.00164	0.00199	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Entecavir—hepatitis B	0.00163	0.00198	CcSEcCtD
Lenalidomide—Dysphagia—Lamivudine—hepatitis B	0.00163	0.00198	CcSEcCtD
Lenalidomide—Influenza—Lamivudine—hepatitis B	0.00163	0.00198	CcSEcCtD
Lenalidomide—Nervous system disorder—Telbivudine—hepatitis B	0.00161	0.00196	CcSEcCtD
Lenalidomide—Thrombocytopenia—Telbivudine—hepatitis B	0.00161	0.00195	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—CTNNB1—hepatitis B	0.0016	0.0156	CbGpPWpGaD
Lenalidomide—Pancreatitis—Lamivudine—hepatitis B	0.00159	0.00194	CcSEcCtD
Lenalidomide—Skin disorder—Telbivudine—hepatitis B	0.00159	0.00194	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.00159	0.00194	CcSEcCtD
Lenalidomide—Sweating increased—Lamivudine—hepatitis B	0.00158	0.00192	CcSEcCtD
Lenalidomide—Body temperature increased—Entecavir—hepatitis B	0.00158	0.00192	CcSEcCtD
Lenalidomide—Abdominal pain—Entecavir—hepatitis B	0.00158	0.00192	CcSEcCtD
Lenalidomide—Bronchitis—Lamivudine—hepatitis B	0.00156	0.0019	CcSEcCtD
Lenalidomide—Abdominal discomfort—Lamivudine—hepatitis B	0.00156	0.00189	CcSEcCtD
Lenalidomide—Pancytopenia—Lamivudine—hepatitis B	0.00154	0.00188	CcSEcCtD
Lenalidomide—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.00154	0.00187	CcSEcCtD
Lenalidomide—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.00154	0.00187	CcSEcCtD
Lenalidomide—Dysuria—Lamivudine—hepatitis B	0.00152	0.00185	CcSEcCtD
Lenalidomide—Neutropenia—Lamivudine—hepatitis B	0.00152	0.00185	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—CTNNB1—hepatitis B	0.00151	0.0148	CbGpPWpGaD
Lenalidomide—Pollakiuria—Lamivudine—hepatitis B	0.0015	0.00183	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.0015	0.00182	CcSEcCtD
Lenalidomide—Insomnia—Telbivudine—hepatitis B	0.00148	0.0018	CcSEcCtD
Lenalidomide—Paraesthesia—Telbivudine—hepatitis B	0.00147	0.00179	CcSEcCtD
Lenalidomide—Hyperglycaemia—Lamivudine—hepatitis B	0.00147	0.00178	CcSEcCtD
Lenalidomide—Depression—Lamivudine—hepatitis B	0.00145	0.00176	CcSEcCtD
Lenalidomide—Dyspepsia—Telbivudine—hepatitis B	0.00144	0.00176	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Lamivudine—hepatitis B	0.00144	0.00175	CcSEcCtD
Lenalidomide—Asthenia—Entecavir—hepatitis B	0.00143	0.00174	CcSEcCtD
Lenalidomide—Renal failure—Lamivudine—hepatitis B	0.00143	0.00173	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Lamivudine—hepatitis B	0.00142	0.00173	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Telbivudine—hepatitis B	0.00142	0.00172	CcSEcCtD
Lenalidomide—Fatigue—Telbivudine—hepatitis B	0.00142	0.00172	CcSEcCtD
Lenalidomide—Stomatitis—Lamivudine—hepatitis B	0.00141	0.00172	CcSEcCtD
Lenalidomide—Pain—Telbivudine—hepatitis B	0.0014	0.00171	CcSEcCtD
Lenalidomide—Asthenia—Adefovir Dipivoxil—hepatitis B	0.0014	0.0017	CcSEcCtD
Lenalidomide—Sweating—Lamivudine—hepatitis B	0.00139	0.00169	CcSEcCtD
Lenalidomide—Pruritus—Adefovir Dipivoxil—hepatitis B	0.00138	0.00168	CcSEcCtD
Lenalidomide—CDH5—Cell-Cell communication—CTNNB1—hepatitis B	0.00137	0.0134	CbGpPWpGaD
Lenalidomide—Hepatobiliary disease—Lamivudine—hepatitis B	0.00137	0.00167	CcSEcCtD
Lenalidomide—Epistaxis—Lamivudine—hepatitis B	0.00137	0.00166	CcSEcCtD
Lenalidomide—Diarrhoea—Entecavir—hepatitis B	0.00137	0.00166	CcSEcCtD
Lenalidomide—Sinusitis—Lamivudine—hepatitis B	0.00136	0.00165	CcSEcCtD
Lenalidomide—Agranulocytosis—Lamivudine—hepatitis B	0.00135	0.00164	CcSEcCtD
Lenalidomide—Feeling abnormal—Telbivudine—hepatitis B	0.00135	0.00164	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Telbivudine—hepatitis B	0.00134	0.00163	CcSEcCtD
Lenalidomide—PTGS2—blood—hepatitis B	0.00134	0.0314	CbGeAlD
Lenalidomide—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.00133	0.00162	CcSEcCtD
Lenalidomide—Dizziness—Entecavir—hepatitis B	0.00132	0.00161	CcSEcCtD
Lenalidomide—Rhinitis—Lamivudine—hepatitis B	0.00131	0.00159	CcSEcCtD
Lenalidomide—Hepatitis—Lamivudine—hepatitis B	0.0013	0.00158	CcSEcCtD
Lenalidomide—Body temperature increased—Telbivudine—hepatitis B	0.0013	0.00158	CcSEcCtD
Lenalidomide—Abdominal pain—Telbivudine—hepatitis B	0.0013	0.00158	CcSEcCtD
Lenalidomide—Hypoaesthesia—Lamivudine—hepatitis B	0.0013	0.00157	CcSEcCtD
Lenalidomide—Pharyngitis—Lamivudine—hepatitis B	0.00129	0.00157	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—GGT2—hepatitis B	0.00128	0.0125	CbGpPWpGaD
Lenalidomide—Connective tissue disorder—Lamivudine—hepatitis B	0.00128	0.00155	CcSEcCtD
Lenalidomide—Vomiting—Entecavir—hepatitis B	0.00127	0.00154	CcSEcCtD
Lenalidomide—Rash—Entecavir—hepatitis B	0.00126	0.00153	CcSEcCtD
Lenalidomide—Dermatitis—Entecavir—hepatitis B	0.00126	0.00153	CcSEcCtD
Lenalidomide—Headache—Entecavir—hepatitis B	0.00125	0.00152	CcSEcCtD
Lenalidomide—Vomiting—Adefovir Dipivoxil—hepatitis B	0.00124	0.00151	CcSEcCtD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—CYP2A6—hepatitis B	0.00124	0.0121	CbGpPWpGaD
Lenalidomide—Erythema multiforme—Lamivudine—hepatitis B	0.00123	0.0015	CcSEcCtD
Lenalidomide—Rash—Adefovir Dipivoxil—hepatitis B	0.00123	0.00149	CcSEcCtD
Lenalidomide—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.00123	0.00149	CcSEcCtD
Lenalidomide—Headache—Adefovir Dipivoxil—hepatitis B	0.00122	0.00148	CcSEcCtD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—hepatitis B	0.00122	0.0119	CbGpPWpGaD
Lenalidomide—Nausea—Entecavir—hepatitis B	0.00119	0.00144	CcSEcCtD
Lenalidomide—Asthenia—Telbivudine—hepatitis B	0.00118	0.00143	CcSEcCtD
Lenalidomide—Immune system disorder—Lamivudine—hepatitis B	0.00118	0.00143	CcSEcCtD
Lenalidomide—Mediastinal disorder—Lamivudine—hepatitis B	0.00117	0.00143	CcSEcCtD
Lenalidomide—Chills—Lamivudine—hepatitis B	0.00117	0.00142	CcSEcCtD
Lenalidomide—Pruritus—Telbivudine—hepatitis B	0.00116	0.00141	CcSEcCtD
Lenalidomide—Nausea—Adefovir Dipivoxil—hepatitis B	0.00116	0.00141	CcSEcCtD
Lenalidomide—Alopecia—Lamivudine—hepatitis B	0.00115	0.0014	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DPA1—hepatitis B	0.00115	0.0112	CbGpPWpGaD
Lenalidomide—Malnutrition—Lamivudine—hepatitis B	0.00113	0.00138	CcSEcCtD
Lenalidomide—Erythema—Lamivudine—hepatitis B	0.00113	0.00138	CcSEcCtD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—FASLG—hepatitis B	0.00113	0.011	CbGpPWpGaD
Lenalidomide—Diarrhoea—Telbivudine—hepatitis B	0.00112	0.00136	CcSEcCtD
Lenalidomide—Flatulence—Lamivudine—hepatitis B	0.00112	0.00136	CcSEcCtD
Lenalidomide—Tension—Lamivudine—hepatitis B	0.00111	0.00135	CcSEcCtD
Lenalidomide—Dysgeusia—Lamivudine—hepatitis B	0.00111	0.00135	CcSEcCtD
Lenalidomide—Nervousness—Lamivudine—hepatitis B	0.0011	0.00134	CcSEcCtD
Lenalidomide—Back pain—Lamivudine—hepatitis B	0.0011	0.00133	CcSEcCtD
Lenalidomide—Muscle spasms—Lamivudine—hepatitis B	0.00109	0.00132	CcSEcCtD
Lenalidomide—Dizziness—Telbivudine—hepatitis B	0.00109	0.00132	CcSEcCtD
Lenalidomide—Tremor—Lamivudine—hepatitis B	0.00106	0.00129	CcSEcCtD
Lenalidomide—Ill-defined disorder—Lamivudine—hepatitis B	0.00105	0.00128	CcSEcCtD
Lenalidomide—Anaemia—Lamivudine—hepatitis B	0.00105	0.00127	CcSEcCtD
Lenalidomide—PTGS2—liver—hepatitis B	0.00105	0.0246	CbGeAlD
Lenalidomide—Vomiting—Telbivudine—hepatitis B	0.00104	0.00127	CcSEcCtD
Lenalidomide—Angioedema—Lamivudine—hepatitis B	0.00104	0.00126	CcSEcCtD
Lenalidomide—Rash—Telbivudine—hepatitis B	0.00104	0.00126	CcSEcCtD
Lenalidomide—Dermatitis—Telbivudine—hepatitis B	0.00103	0.00126	CcSEcCtD
Lenalidomide—Headache—Telbivudine—hepatitis B	0.00103	0.00125	CcSEcCtD
Lenalidomide—Malaise—Lamivudine—hepatitis B	0.00102	0.00124	CcSEcCtD
Lenalidomide—Vertigo—Lamivudine—hepatitis B	0.00102	0.00124	CcSEcCtD
Lenalidomide—Syncope—Lamivudine—hepatitis B	0.00102	0.00123	CcSEcCtD
Lenalidomide—Leukopenia—Lamivudine—hepatitis B	0.00101	0.00123	CcSEcCtD
Lenalidomide—Loss of consciousness—Lamivudine—hepatitis B	0.000996	0.00121	CcSEcCtD
Lenalidomide—Cough—Lamivudine—hepatitis B	0.000989	0.0012	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MIF—hepatitis B	0.000978	0.00953	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—hepatitis B	0.000977	0.00952	CbGpPWpGaD
Lenalidomide—Nausea—Telbivudine—hepatitis B	0.000975	0.00118	CcSEcCtD
Lenalidomide—Myalgia—Lamivudine—hepatitis B	0.000965	0.00117	CcSEcCtD
Lenalidomide—Chest pain—Lamivudine—hepatitis B	0.000965	0.00117	CcSEcCtD
Lenalidomide—Arthralgia—Lamivudine—hepatitis B	0.000965	0.00117	CcSEcCtD
Lenalidomide—Anxiety—Lamivudine—hepatitis B	0.000962	0.00117	CcSEcCtD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—hepatitis B	0.00096	0.00935	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.000958	0.00116	CcSEcCtD
Lenalidomide—PTGS2—Arachidonic acid metabolism—GGT1—hepatitis B	0.000955	0.00931	CbGpPWpGaD
Lenalidomide—Discomfort—Lamivudine—hepatitis B	0.000953	0.00116	CcSEcCtD
Lenalidomide—Dry mouth—Lamivudine—hepatitis B	0.000944	0.00115	CcSEcCtD
Lenalidomide—Confusional state—Lamivudine—hepatitis B	0.000933	0.00113	CcSEcCtD
Lenalidomide—Oedema—Lamivudine—hepatitis B	0.000925	0.00112	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—IL6—hepatitis B	0.000922	0.00898	CbGpPWpGaD
Lenalidomide—Infection—Lamivudine—hepatitis B	0.000919	0.00112	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—RIT2—hepatitis B	0.000919	0.00895	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SAG—hepatitis B	0.000919	0.00895	CbGpPWpGaD
Lenalidomide—Shock—Lamivudine—hepatitis B	0.00091	0.00111	CcSEcCtD
Lenalidomide—Nervous system disorder—Lamivudine—hepatitis B	0.000907	0.0011	CcSEcCtD
Lenalidomide—Thrombocytopenia—Lamivudine—hepatitis B	0.000906	0.0011	CcSEcCtD
Lenalidomide—Skin disorder—Lamivudine—hepatitis B	0.000899	0.00109	CcSEcCtD
Lenalidomide—Hyperhidrosis—Lamivudine—hepatitis B	0.000894	0.00109	CcSEcCtD
Lenalidomide—Anorexia—Lamivudine—hepatitis B	0.000882	0.00107	CcSEcCtD
Lenalidomide—Hypotension—Lamivudine—hepatitis B	0.000864	0.00105	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.000843	0.00102	CcSEcCtD
Lenalidomide—Insomnia—Lamivudine—hepatitis B	0.000837	0.00102	CcSEcCtD
Lenalidomide—Paraesthesia—Lamivudine—hepatitis B	0.000831	0.00101	CcSEcCtD
Lenalidomide—ABCB1—blood—hepatitis B	0.000827	0.0194	CbGeAlD
Lenalidomide—Dyspnoea—Lamivudine—hepatitis B	0.000825	0.001	CcSEcCtD
Lenalidomide—Somnolence—Lamivudine—hepatitis B	0.000822	0.000999	CcSEcCtD
Lenalidomide—Dyspepsia—Lamivudine—hepatitis B	0.000814	0.000989	CcSEcCtD
Lenalidomide—Decreased appetite—Lamivudine—hepatitis B	0.000804	0.000977	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—hepatitis B	0.000804	0.00784	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Lamivudine—hepatitis B	0.000799	0.00097	CcSEcCtD
Lenalidomide—Fatigue—Lamivudine—hepatitis B	0.000798	0.000969	CcSEcCtD
Lenalidomide—Pain—Lamivudine—hepatitis B	0.000791	0.000961	CcSEcCtD
Lenalidomide—Constipation—Lamivudine—hepatitis B	0.000791	0.000961	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—hepatitis B	0.000789	0.00768	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Lamivudine—hepatitis B	0.000762	0.000926	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Lamivudine—hepatitis B	0.000756	0.000919	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—HNF4A—hepatitis B	0.000739	0.0072	CbGpPWpGaD
Lenalidomide—Urticaria—Lamivudine—hepatitis B	0.000735	0.000893	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—hepatitis B	0.000733	0.00714	CbGpPWpGaD
Lenalidomide—Abdominal pain—Lamivudine—hepatitis B	0.000731	0.000888	CcSEcCtD
Lenalidomide—Body temperature increased—Lamivudine—hepatitis B	0.000731	0.000888	CcSEcCtD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—hepatitis B	0.000717	0.00699	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Lamivudine—hepatitis B	0.000682	0.000828	CcSEcCtD
Lenalidomide—Asthenia—Lamivudine—hepatitis B	0.000664	0.000806	CcSEcCtD
Lenalidomide—Pruritus—Lamivudine—hepatitis B	0.000655	0.000795	CcSEcCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—hepatitis B	0.000651	0.00634	CbGpPWpGaD
Lenalidomide—ABCB1—liver—hepatitis B	0.000647	0.0152	CbGeAlD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—hepatitis B	0.000637	0.00621	CbGpPWpGaD
Lenalidomide—Diarrhoea—Lamivudine—hepatitis B	0.000633	0.000769	CcSEcCtD
Lenalidomide—Dizziness—Lamivudine—hepatitis B	0.000612	0.000743	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—GGT1—hepatitis B	0.000608	0.00592	CbGpPWpGaD
Lenalidomide—Vomiting—Lamivudine—hepatitis B	0.000588	0.000715	CcSEcCtD
Lenalidomide—Rash—Lamivudine—hepatitis B	0.000583	0.000709	CcSEcCtD
Lenalidomide—Dermatitis—Lamivudine—hepatitis B	0.000583	0.000708	CcSEcCtD
Lenalidomide—Headache—Lamivudine—hepatitis B	0.00058	0.000704	CcSEcCtD
Lenalidomide—Nausea—Lamivudine—hepatitis B	0.00055	0.000667	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DPB1—hepatitis B	0.000526	0.00512	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—hepatitis B	0.000525	0.00512	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—hepatitis B	0.000464	0.00452	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL10—hepatitis B	0.000463	0.00451	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—hepatitis B	0.000445	0.00434	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—hepatitis B	0.000415	0.00405	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—hepatitis B	0.000412	0.00402	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—hepatitis B	0.000412	0.00401	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—F2—hepatitis B	0.000389	0.00379	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD40LG—hepatitis B	0.000388	0.00378	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL10—hepatitis B	0.000388	0.00378	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL10—hepatitis B	0.000363	0.00353	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FASLG—hepatitis B	0.00036	0.00351	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—hepatitis B	0.000352	0.00343	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FAS—hepatitis B	0.000348	0.00339	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—NOS2—hepatitis B	0.000343	0.00334	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-A—hepatitis B	0.000342	0.00333	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ALB—hepatitis B	0.000323	0.00315	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—hepatitis B	0.000321	0.00313	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TLR4—hepatitis B	0.00032	0.00312	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—hepatitis B	0.000316	0.00308	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—hepatitis B	0.000314	0.00306	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DRB1—hepatitis B	0.000312	0.00304	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—NOS2—hepatitis B	0.000304	0.00296	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1B1—hepatitis B	0.000301	0.00293	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—hepatitis B	0.0003	0.00292	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CD4—hepatitis B	0.000296	0.00288	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IFNG—hepatitis B	0.000295	0.00287	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCR5—hepatitis B	0.000281	0.00274	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1A—hepatitis B	0.000257	0.0025	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—hepatitis B	0.000251	0.00244	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—NFKB1—hepatitis B	0.000245	0.00239	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—hepatitis B	0.000242	0.00236	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—F2—hepatitis B	0.000241	0.00235	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IFNG—hepatitis B	0.000233	0.00227	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IFNG—hepatitis B	0.000228	0.00222	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—hepatitis B	0.000207	0.00202	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL2—hepatitis B	0.000203	0.00197	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—hepatitis B	0.000191	0.00186	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—hepatitis B	0.000178	0.00173	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOBEC3G—hepatitis B	0.000177	0.00173	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SAG—hepatitis B	0.000177	0.00173	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—hepatitis B	0.000171	0.00167	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2—hepatitis B	0.000163	0.00158	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—hepatitis B	0.000162	0.00158	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—hepatitis B	0.000158	0.00154	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—hepatitis B	0.000157	0.00153	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—hepatitis B	0.000154	0.0015	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1A—hepatitis B	0.000153	0.00149	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTEN—hepatitis B	0.000153	0.00149	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NFKB1—hepatitis B	0.000152	0.00148	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—hepatitis B	0.000151	0.00147	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—hepatitis B	0.000148	0.00144	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	0.000137	0.00133	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	0.000136	0.00133	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKR1B1—hepatitis B	0.000134	0.00131	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—hepatitis B	0.000133	0.0013	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	0.000133	0.0013	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	0.000133	0.00129	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	0.000132	0.00129	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GGT2—hepatitis B	0.000129	0.00125	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—hepatitis B	0.000127	0.00124	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—hepatitis B	0.000122	0.00119	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	0.00011	0.00107	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—hepatitis B	0.000104	0.00102	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—hepatitis B	0.000103	0.001	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	9.65e-05	0.00094	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—hepatitis B	9.55e-05	0.000931	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKR1B1—hepatitis B	9.5e-05	0.000926	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	9.43e-05	0.000919	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	9.41e-05	0.000916	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	9.36e-05	0.000912	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GGT2—hepatitis B	9.11e-05	0.000888	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	9.06e-05	0.000882	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GOT2—hepatitis B	8.41e-05	0.00082	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	7.8e-05	0.00076	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP2A6—hepatitis B	7.79e-05	0.000759	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hepatitis B	7.28e-05	0.000709	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—hepatitis B	7.26e-05	0.000708	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GOT1—hepatitis B	7.26e-05	0.000707	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GOT2—hepatitis B	7.04e-05	0.000686	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	6.42e-05	0.000625	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GOT1—hepatitis B	6.08e-05	0.000592	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GGT1—hepatitis B	6.08e-05	0.000592	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	5.54e-05	0.00054	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP2A6—hepatitis B	5.52e-05	0.000538	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CCR5—hepatitis B	5.42e-05	0.000528	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HLA-A—hepatitis B	5.28e-05	0.000515	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GOT2—hepatitis B	4.99e-05	0.000487	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—hepatitis B	4.89e-05	0.000477	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS2—hepatitis B	4.59e-05	0.000448	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GOT1—hepatitis B	4.31e-05	0.00042	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GGT1—hepatitis B	4.31e-05	0.00042	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—hepatitis B	3.4e-05	0.000332	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—hepatitis B	3.23e-05	0.000315	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—hepatitis B	3.02e-05	0.000295	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1A—hepatitis B	2.95e-05	0.000288	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—hepatitis B	2.95e-05	0.000287	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—hepatitis B	2.47e-05	0.00024	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—hepatitis B	2.44e-05	0.000238	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—hepatitis B	2.29e-05	0.000223	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—hepatitis B	1.84e-05	0.000179	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—hepatitis B	1.75e-05	0.00017	CbGpPWpGaD
